Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Primus Partners, iSPIRT unveil roadmap for global Digital Public Infrastructure adoption
- Social media addiction, sedentary habits eating into health, productivity potential: Economic Survey
- Primus Partners: 59 per cent of Indian MSMEs Find Online Advertising Instrumental in Achieving Diverse Business Goals
- Budget 2023: Start-ups hail extension of tax holiday, loss carry forward period
